{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T22:22:44Z","timestamp":1747606964814,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen GmbH (Munich, Germany) and Amgen Europe GmbH (Rotkreuz, Switzerland)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are limited data guiding choice of re-induction therapies for patients with relapsed\/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany who received re-induction therapy in second line (78%; <jats:italic>n<\/jats:italic>\u2009=\u2009134) or third line (22%; <jats:italic>n<\/jats:italic>\u2009=\u200937) prior to re-SCT. Index therapy was defined as first completed re-induction therapy for planned myeloablative conditioning and SCT in second\/third line within the eligibility period (1\/2016\u201312\/2019). Most common pre-index first line and maintenance therapy used were bortezomib-based combinations (91%; <jats:italic>n<\/jats:italic>\u2009=\u2009155\/171) and lenalidomide (55%; <jats:italic>n<\/jats:italic>\u2009=\u200929\/53), respectively. Median duration of index therapy line was 9 months; carfilzomib-based combinations were the most widely used in second\/third line re-induction therapy (49%; <jats:italic>n<\/jats:italic>\u2009=\u200983\/171), followed by daratumumab-based combinations (21%; <jats:italic>n<\/jats:italic>\u2009=\u200936\/171). Overall response rates in second\/third line were 87% after re-induction and 96% after SCT; median time to next treatment line after start of index therapy was 31 months; median progression-free survival (PFS) was 29 months; and median overall survival after index date was not reached. Based on these data, re-induction therapy with salvage SCT appears to be beneficial in selected patients with RRMM in clinical practice in Germany, translating into deep responses, long PFS and prolonged time to next treatment.<\/jats:p>","DOI":"10.1038\/s41409-024-02208-3","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T07:47:36Z","timestamp":1710402456000},"page":"880-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed\/refractory multiple myeloma in Germany"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-3149","authenticated-orcid":false,"given":"Sandra","family":"Sauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Flossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiltrud","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Ertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Friederich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Thun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2208_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606.","journal-title":"BMC Cancer"},{"key":"2208_CR2","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9:e670\u2013e677.","journal-title":"Lancet Haematol"},{"key":"2208_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.13537","volume":"171","author":"D Pulte","year":"2015","unstructured":"Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B, et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol. 2015;171:189\u201396.","journal-title":"Br J Haematol"},{"key":"2208_CR4","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/cancers12102885","volume":"12","author":"A Bobin","year":"2020","unstructured":"Bobin A, Liuu E, Moya N, Gruchet C, Sabirou F, L\u00e9vy A, et al. Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020. Cancers (Basel). 2020;12:2885.","journal-title":"Cancers (Basel)"},{"key":"2208_CR5","first-page":"253","volume":"119","author":"V Piechotta","year":"2022","unstructured":"Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C. Patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Dtsch Arztebl Int. 2022;119:253\u201360.","journal-title":"Dtsch Arztebl Int"},{"key":"2208_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5","volume":"12","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12:98.","journal-title":"Blood Cancer J"},{"key":"2208_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.18025","volume":"197","author":"D Swan","year":"2022","unstructured":"Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022;197:82\u201396.","journal-title":"Br J Haematol"},{"key":"2208_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.","journal-title":"Blood Cancer J"},{"key":"2208_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"2208_CR10","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u2013e118.","journal-title":"Lancet Oncol"},{"key":"2208_CR11","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.3390\/cancers13184706","volume":"13","author":"MA Baertsch","year":"2021","unstructured":"Baertsch MA, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, et al. Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 2021;13:4706.","journal-title":"Cancers (Basel)"},{"key":"2208_CR12","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","volume":"3","author":"G Cook","year":"2016","unstructured":"Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340\u2013351.","journal-title":"Lancet Haematol"},{"key":"2208_CR13","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","volume":"35","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021;35:1134\u201344.","journal-title":"Leukemia"},{"key":"2208_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbmt.2014.12.026","volume":"21","author":"SA Holstein","year":"2015","unstructured":"Holstein SA, Richardson PG, Laubach JP, McCarthy PL. Management of relapsed multiple myeloma after autologous stem cell transplant. Biol Blood Marrow Transplant. 2015;21:793\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2208_CR15","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.clml.2020.08.026","volume":"21","author":"AO Abdallah","year":"2021","unstructured":"Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, et al. Outcomes of daratumumab, pomalidomide, and dexamethasone, followed by high-dose chemotherapy and autologous stem cell transplantation, in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21:e212\u2013e219.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2208_CR16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00277-017-3140-5","volume":"96","author":"BA Zannetti","year":"2017","unstructured":"Zannetti BA, Tacchetti P, Pantani L, Gamberi B, Tosi P, Rocchi S, et al. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. Ann Hematol. 2017;96:2071\u20138.","journal-title":"Ann Hematol"},{"key":"2208_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013e548.","journal-title":"Lancet Oncol"},{"key":"2208_CR18","unstructured":"International Myeloma Working Group (IMWG). International Myeloma Working Group (IMWG) uniform response criteria for multiple myeloma. 2020. https:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple. Accessed 20 Jun 2023."},{"key":"2208_CR19","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52\u2013iv61.","journal-title":"Ann Oncol"},{"key":"2208_CR20","unstructured":"Robert Koch Institut. Overweight and obesity. https:\/\/www.rki.de\/EN\/Content\/Health_Monitoring\/Main_Topics\/Overweight_Obesity\/obesity_node.html. Accessed 20 Jun 2023."},{"key":"2208_CR21","unstructured":"European Medicines Agency. Daralex. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/darzalex. Accessed 20 Jun 2023."},{"key":"2208_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s12325-021-02022-z","volume":"39","author":"HT Steinmetz","year":"2022","unstructured":"Steinmetz HT, Singh M, Milce J, Haidar M, Rieth A, Lebioda A, et al. Management of patients with relapsed and\/or refractory multiple myeloma treated with novel combination therapies in routine clinical practice in Germany. Adv Ther. 2022;39:1247\u201366.","journal-title":"Adv Ther"},{"key":"2208_CR23","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u2013e468.","journal-title":"Lancet Haematol"},{"key":"2208_CR24","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617\u201329.","journal-title":"Lancet Oncol"},{"key":"2208_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40487-021-00143-7","volume":"9","author":"D Karam","year":"2021","unstructured":"Karam D, Kumar S. Post-transplant maintenance treatment options in multiple myeloma. Oncol Ther. 2021;9:69\u201388.","journal-title":"Oncol Ther"},{"key":"2208_CR26","unstructured":"European Medicines Agency. Lenalidomide Accord. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lenalidomide-accord#authorisation-details-section. Accessed 20 Jun 2023."},{"key":"2208_CR27","doi-asserted-by":"publisher","first-page":"Abstract P882","DOI":"10.1097\/01.HS9.0000970432.75766.0c","volume":"7","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja J, et al. Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the Phase 2 MM-014 study. Hemasphere. 2023;7:Abstract P882.","journal-title":"Hemasphere"},{"key":"2208_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/hon.2499","volume":"36","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, et al. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: a subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018;36:463\u201370.","journal-title":"Hematol Oncol"},{"key":"2208_CR29","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1182\/blood-2022-164572","volume":"140","author":"YC Cohen","year":"2022","unstructured":"Cohen YC, Gatt ME, Luttwak E, Lavi N, Ganzel C, Chubar E, et al. Daratumumab carfilzomib lenalidomide dexamethasone provides effective salvage for functionally and cytogenetically high-risk myeloma patients, except those expressing module-1 transcriptional signature: extended follow-up from Kydar multicenter clinical\/translational trial. Blood. 2022;140:4426\u20137.","journal-title":"Blood"},{"key":"2208_CR30","doi-asserted-by":"publisher","first-page":"1162990","DOI":"10.3389\/fonc.2023.1162990","volume":"13","author":"E Antonioli","year":"2023","unstructured":"Antonioli E, Pilerci S, Attucci I, Buda G, Gozzetti A, Candi V, et al. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network. Front Oncol. 2023;13:1162990.","journal-title":"Front Oncol"},{"key":"2208_CR31","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/S2152-2650(21)02343-0","volume":"21","author":"G Shah","year":"2021","unstructured":"Shah G, Bal S, Rodriguez C, Chhabra S, Bayer R, Costa L, et al. Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed\/refractory myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol. Clin Lymphoma Myeloma Leuk. 2021;21:S158\u2013S159.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2208_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ejh.13709","volume":"108","author":"H Gregersen","year":"2022","unstructured":"Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, et al. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group. Eur J Haematol. 2022;108:34\u201344.","journal-title":"Eur J Haematol"},{"key":"2208_CR33","doi-asserted-by":"crossref","unstructured":"Terpos E, Slama B, Zambello R, Badelita SN, Katodritou E, Caers J, et al. Real-world evidence of the use of carfilzomib among multiple myeloma patients with at least one prior therapy across 10 European countries and Israel. Blood. 2020;136:38\u201339.","DOI":"10.1182\/blood-2020-134475"},{"key":"2208_CR34","doi-asserted-by":"publisher","first-page":"P957","DOI":"10.1097\/01.HS9.0000846696.43332.f6","volume":"6","author":"R Tilmont","year":"2022","unstructured":"Tilmont R, Yakoub-Agha I, Eikema DJ, Zinger N, Haenel M, Schaap N, et al. Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the Chronic Malignancies Working Party of EBMT. Hemasphere. 2022;6:P957.","journal-title":"Hemasphere"},{"key":"2208_CR35","doi-asserted-by":"publisher","first-page":"P900","DOI":"10.1097\/01.HS9.0000846472.10254.dd","volume":"6","author":"S Duarte","year":"2022","unstructured":"Duarte S, Roque A, Mota D, Carda J, Geraldes C. Salvage autologous stem cell transplant in relapsed multiple myeloma: a single centre experience. Hemasphere. 2022;6:P900.","journal-title":"Hemasphere"},{"key":"2208_CR36","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Costa LJ, Facon T, Harousseau JL, Manier S, Perrot A, et al. Current advances in multiple myeloma: a post International Myeloma Society (IMS 2022) round table debate by the International Academy for Clinical Hematology (IACH). Clin Hematol Int. 2023;5:112\u201321.","DOI":"10.1007\/s44228-023-00036-8"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02208-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T07:07:22Z","timestamp":1717744042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02208-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02208-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS: Amgen: honoraria, research funding, travel support; Bristol Myers Squibb: honoraria; Janssen: honoraria, travel support; Sanofi: honoraria, travel support. ME: Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm, Novartis and Takeda: educational and trial support; Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis and Takeda: honoraria and consultancy fees. KTG: Amgen and Novartis: honoraria, research funding; GSK, Janssen, Sanofi and Takeda: honoraria. CK: Amgen: honoraria and research funding; GSK, Janssen and KiteGilead: honoraria and travel support; Sanofi-Aventis and Takeda: honoraria. MH: Amgen, Bayer Vital, Celgene, Gilead, GSK, Jazz Pharmaceuticals, Novartis, Roche, Sanofi, Sobi and Takeda: honoraria. MSH: Amgen GmbH, Bristol Myers Squibb GmbH & Co. KG, Celgene GmbH, GSK GmbH & Co. KG, Kite\/Pharma Gilead, Sanofi-Aventis Deutschland GmbH, Shionogi GmbH and Stemline Therapeutics (no individual payment): consultancy, financial support of educational meetings; Celgene GmbH (no individual payment), Janssen-Cilag GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG, Takeda Pharma Vertrieb GmbH & Co. KG and Vifor Pharma Deutschland GmbH: financial support of educational meetings. HS: Amgen, Bristol Myers Squibb, Celgene, Janssen and Novartis: honoraria, travel support and research funding; Takeda: honoraria. MSR: Amgen, Bristol Myers Squibb and Novartis: consultancy, honoraria and research funding; Celgene: consultancy and honoraria. BT is an employee of IQVIA who received funding from Amgen to conduct this research study. CF, HH, FE and AF are employees of Amgen GmbH and hold Amgen stock. SP is an employee of Amgen Ltd and holds Amgen stock. This study was funded by Amgen (Germany and Europe) GmbH. Medical writing support was provided by Carine Thual of Amgen (Europe) GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}